Company intelligence / Profile preview

NoBrainer Imaging Centers

Vancouver, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

NoBrainer Imaging Centers, now acquired by Algernon Pharmaceuticals, held exclusive master franchise rights to open and operate Alzheimer’s diagnostic and treatment centers using advanced PET imaging and infusion services; the first U.S. clinic is scheduled to open in Q4 2025, aiming to offer screening, PET-based diagnostics of amyloid plaques, and approved Alzheimer's infusion therapies, with further expansion anticipated[1][5][6][7][8].

Therapeutic areas: OncologyNeurology
Modalities: Device
Industry: Non-Academic Healthcare

Partnerships

Positrigo (PET imaging device supplier)

Beyond the preview

Go deeper on NoBrainer Imaging Centers.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NoBrainer Imaging Centers.

Explore the full profile